Topiramate: A new antiepileptic drug

American Journal of Health-System Pharmacy

Volumn 55, Issue 6, 1998, Pages 554-562

  Markind, Jan E ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University HealthSystem Consortium   (United States)

Author keywords

Anticonvulsants; Dosage; Drug interactions; Epilepsy; Pharmacokinetics; Topiramate; Toxicity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CENTRAL DEPRESSANT AGENT; CYTOCHROME P450; DIGOXIN; NEW DRUG; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADJUVANT THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG PROTEIN BINDING; FOCAL EPILEPSY; HUMAN; LENNOX GASTAUT SYNDROME; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 0032521073     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.6.554     Document Type: Review

References (42)

1. Shank RP, Gardocki JF, Vaught JL et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 1994; 35:450-60.
2. Ben-Menachem E. Potential antiepileptic drugs: topiramate. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven; 1995:1063-70.
3. Bourgeois BFD. Drug interaction profile of topiramate. Epilepsia. 1996; 37(suppl 2):S14-7.
4. Topamax package insert. Raritan, NJ: McNeil; 1996.
5. Rogowski MA, Porter RJ. Antiepileptic drugs: pharmacologic mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990; 42:223-86.
6. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia. 1993; 34(suppl 2):123. Abstract.
7. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia. 1996; 37(suppl 2):S8-13.
8. Easterling DE, Zakszewski T, Moyer MD et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia. 1988; 29:662. Abstract.
9. Doose DR, Scott VV, Margul BL et al. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia. 1988; 29:662. Abstract.
10. Doose DR, Walker SA, Sachdeo R et al. Steady-state pharmacokinetics of Tegretol (carbamazepine) and Topamax (topiramate) in patients with epilepsy on monotherapy and during combination therapy. Epilepsia. 1994; 35(suppl 8):54. Abstract.
11. Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia. 1994; 35(suppl 8):54. Abstract.
12. Liao S, Rosenfeld WE, Palmer M et al. Steady-state pharmacokinetics of topiramate and valproic acid in patients with epilepsy on monotherapy, and during combination therapy. Epilepsia. 1994; 35(suppl 8):117. Abstract.
13. Gisclon LG, Riffitts JM, Sica DA et al. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharm Res. 1993; 10(suppl):S-397. Abstract.
14. Privitera M, Fincham R, Penry J et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology. 1996; 46:1678-83.
15. Faught E, Wilder BJ, Ramsay RE et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology. 1996; 46:1684-90.
16. Sachdeo SK, Sachdeo RC, Reife RA et al. Topiramate: double-blind trial as monotherapy. Epilepsia. 1995; 36(suppl 4):33. Abstract.
17. Glauser TA, Olberding L, Clark P et al. Topiramate monotherapy substitution in children with partial epilepsy. Epilepsia. 1996; 37(suppl 4):98. Abstract.
18. Michelucci R, Passarelli D, Tassinari CA. Topiramate in the treatment of refractory epilepsy: a 2 year long-term follow-up. Epilepsia. 1996; 37(suppl 4):70. Abstract.
19. Espe-Lillo J, Ritter FJ, Frost MD et al. Safety and efficacy of topiramate in pediatric subjects. Epilepsia. 1994; 35(suppl 8):162. Abstract.
20. Sachdeo R, Kugler S, Wenger E et al. Topiramate in Lennox-Gastaut syndrome. Epilepsia. 1996; 37(suppl 4):118. Abstract.
21. Tassinari CA, Michelucci R, Chauvel P et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 1996; 37: 763-8.
22. Ben-Menachem E, Henriksen O, Dam M et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996; 37:539-43.
23. Biton V, Reife R, Kamin M et al. Topiramate (Topamax) as add-on therapy for patients with primary generalized epilepsy. Neurology. 1996; 46:A176. Abstract.
24. Rosenfeld WE, Holmes GB, Hunt TL et al. Topiramate - effective dosaging enhances potential for success. Epilepsia. 1992; 33(suppl 3):118. Abstract.
25. Espe-Lillo J, Ritter FJ, Frost MD et al. Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types. Epilepsia. 1995; 36(suppl 4):56. Abstract.
26. French JA, Bourgeois BFD, Dreifus FE et al. An open-label multicenter study of topiramate in patients with the Lennox-Gastaut syndrome. Neurology. 1995; 45(suppl 4):A250. Abstract.
27. French JA. Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs. Epilepsia. 1996; 37(suppl 2):S23-6.
28. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996; 37(suppl 2):S18-22.
29. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate. Epilepsia. 1995; 36(suppl 3):S153. Abstract.
30. Privitera M. Long-term cognitive effects of topiramate. Epilepsia. 1995; 36(suppl 3):S152. Abstract.
31. Floren KL, Graves NM, Leppik IE et al. Pharmacokinetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate. Epilepsia. 1989; 30:646. Abstract.
32. Levy RH, Bishop F, Streeter AJ et al. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Epilepsia. 1995; 36(suppl 4):47. Abstract.
33. Liao S, Palmer M. Digoxin and topiramate drug interaction study in male volunteers. Pharm Res. 1993; 10(suppl):S-405. Abstract.
34. Cardinale V, ed. Red book. Montvale, NJ: Medical Economics; 1997.
35. Armstrong EP. Healthcare economics of acute and chronic seizures: the costs of treatment, Paper presented at An Update on Healthcare Economics in Acute and Chronic Seizures. Las Vegas, NV; 1995 Dec 3.
36. Garnett WR. New opportunities for the treatment of epilepsy. Am J Health-Syst Pharm. 1995; 52:88-91.
37. Patsalos PN, Sander JWAS. Newer antiepileptic drugs: towards an improved risk-benefit ratio. Drug Saf. 1994; 11:37-67.
38. Wilder BJ. How about the new antiepileptic drugs? Can J Neurol Sci. 1994; 21(suppl 3):S17-20.
39. Brodie MJ, Porter RJ. New and potential anticonvulsants. Lancet. 1990; 336:425-6.
40. Leach JP, Brodie MJ. New antiepileptic drugs - an explosion of activity. Seizure. 1995; 4:5-17.
41. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med. 1996; 334:1583-90.
42. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet. 1993; 24:441-52.